{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T17:40:38Z","timestamp":1772905238454,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.diagmicrobio.2025.117100","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T06:36:59Z","timestamp":1757140619000},"page":"117100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a rezafungin isolate verification panel and comparison of reference method to ThermoFisher Sensititre YeastOne panel MIC results"],"prefix":"10.1016","volume":"114","author":[{"given":"Jeanna","family":"DiFranco-Fisher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2885-6129","authenticated-orcid":false,"given":"Laura","family":"Koeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2025.117100_bib0001","unstructured":"https:\/\/www.aphl.org\/toolkits\/Pages\/Verification-Validation-Toolkit.aspx."},{"issue":"12","key":"10.1016\/j.diagmicrobio.2025.117100_bib0002","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1128\/jcm.30.12.3138-3145.1992","article-title":"Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests","volume":"30","author":"Espinel-Ingroff","year":"1992","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2025.117100_bib0003","unstructured":"https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K231433.pdf USPI, label (fda.gov)."},{"issue":"12","key":"10.1016\/j.diagmicrobio.2025.117100_bib0004","article-title":"Bringing antimicrobial susceptibility testing for new drugs into the clinical laboratory: removing obstacles in our fight against multidrug-resistant pathogens","volume":"57","author":"Krohn","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2025.117100_bib0005","series-title":"Performance standards for antifungal susceptibility testing of yeasts. CLSI standard. M27M44S","author":"CLSI\u2024","year":"2022"},{"key":"10.1016\/j.diagmicrobio.2025.117100_bib0006","unstructured":"USPI, Rezafungin label (fda.gov)."},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.117100_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01584-23","article-title":"Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis","volume":"68","author":"Locke","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.117100_bib0008","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/jof10050362","article-title":"A mini-review of In vitro data for Candida species, including C. auris, isolated during clinical trials of three new antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin","volume":"10","author":"Espinel-Ingroff","year":"2024","journal-title":"J Fungi (Basel)"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.117100_bib0009","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jof6040262","article-title":"Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garcia-Effron","year":"2020","journal-title":"J Fungi (Basel)"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2025.117100_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00916-23","article-title":"Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis","volume":"67","author":"Roepcke","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2025.117100_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00842-21","article-title":"Population pharmacokinetics of Rezafungin in patients with fungal infections","volume":"65","author":"Rubino","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117100_bib0012","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin","volume":"61","author":"Sandison","year":"2017"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.117100_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.02449-21","article-title":"Evaluation of Rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020)","volume":"60","author":"Carvalhaes","year":"2022","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2025.117100_bib0014","unstructured":"https:\/\/www.fda.gov\/drugs\/development-resources\/antifungal-susceptibility-test-interpretive-criteria."},{"key":"10.1016\/j.diagmicrobio.2025.117100_bib0015","series-title":"CLSI standard M27","article-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","year":"2017"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.117100_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01934-17","article-title":"CLSI methods development and standardization working group of the subcommittee on Antimicrobial susceptibility testing. CLSI Methods Development and Standardization Working Group Best practices for evaluation of antimicrobial susceptibility tests","volume":"56","author":"Humphries","year":"2018","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.117100_bib0017","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cll.2019.05.008","article-title":"We cannot do it alone: the intersection of public health, public policy, and clinical microbiology","volume":"39","author":"Lee","year":"2019","journal-title":"Clin Lab Med"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325004225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325004225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:35:50Z","timestamp":1772847350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889325004225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0732889325004225"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.117100","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a rezafungin isolate verification panel and comparison of reference method to ThermoFisher Sensititre YeastOne panel MIC results","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.117100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117100"}}